Veerhealth Care FY26 revenue rises 86.08% to ₹33.29 crore

2 min read     Updated on 02 Jun 2026, 05:29 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Veerhealth Care Limited reported a total income of ₹33.29 crore for FY26, a rise of 86.08%, with net profit increasing 38.46% to ₹0.54 crore. EBITDA grew 82.68% to ₹3.27 crore, despite a decline in margins. The company announced orders worth ₹16.51 crore during the year and expanded its e-commerce presence, while projecting revenues of ₹70-75 crore for FY27.

powered bylight_fuzz_icon
41249958

*this image is generated using AI for illustrative purposes only.

Veerhealth Care Limited reported a total income of ₹33.29 crore for the financial year ended March 31, 2026, representing a year-on-year growth of 86.08%. The company's net profit for FY26 stood at ₹0.54 crore, an increase of 38.46% compared to the previous year, while EBITDA rose 82.68% to ₹3.27 crore. The growth was driven by the company's focus on expanding its international footprint and strengthening its domestic presence, alongside the addition of new product categories.

The standalone financial results were published in Active Times Newspaper and Mumbai Lakshadeep Newspaper on June 1, 2026, under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. For the quarter ended March 31, 2026, the company reported a net loss of ₹35.37 lakh, contrasting with a profit of ₹40.48 lakh in the preceding quarter ended December 31, 2025. This quarterly decline was attributed to a forex loss of ₹0.31 crore classified as exceptional items and a provision of ₹0.49 crore for deferred tax.

Financial Performance

The company's net worth as of March 31, 2026, stood at ₹2292.32 lakh, compared to ₹2221.88 lakh in the previous year. Earnings per share (EPS) for the full year improved to ₹0.27 from ₹0.20 in FY25. The EBITDA margin for FY26 was 9.82%, a year-on-year decline of 18 basis points, while the net profit margin was 1.62%, a decline of 56 basis points.

Metric FY26 (₹ in lakh) FY25 (₹ in lakh)
Revenue from operations 3248.45 1686.66
Total Revenue 3328.61 1788.93
Total Expenses 3171.82 1726.83
Net Profit 54.40 39.15
Net Worth 2292.32 2221.88

Assets and Liabilities

The company's total assets increased to ₹4417.44 lakh as of March 31, 2026, from ₹3377.01 lakh a year ago. Current assets rose significantly to ₹1847.59 lakh, primarily due to higher trade receivables and inventories. Total equity and liabilities also grew to ₹4417.44 lakh, with total current liabilities reaching ₹1344.61 lakh.

Strategic Developments

During FY26, Veerhealth Care announced orders totaling ₹16.51 crore from various markets, including exports to the USA and domestic marketplaces. The company completed the onboarding of its Ayurveer products on Myntra, expanding its e-commerce presence across platforms such as Amazon, Flipkart, Nykaa, Glowroad, and Jiomart. Additionally, production commenced at a new facility featuring in-house plastic molding for packaging and backward integration.

Looking ahead, the company expects total revenues of ₹70-75 crore with a PAT of 7-10% in FY27. Veerhealth Care aims to reach revenues of ₹100 crore with a PAT of 10% within the next 24 months, supported by ongoing discussions for exports to Russia and scaling operations in the U.S. market.

Board Appointments

The Board of Directors appointed M/s. Vivek P. Joisar & Co., Chartered Accountants, as the Internal Auditor of the company for the financial year 2026-2027. The firm, registered with Firm Registration No. 144543W, brings over five years of combined experience in finance, auditing, taxation, and transaction advisory services. This appointment was made in compliance with Regulation 30 and Part-A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Auditor's Report

M/s. Jayesh R. Shah & Co., Statutory Auditors, issued an unmodified opinion on the standalone financial results. The auditors confirmed that the results are presented in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provide a true and fair view of the company's financial performance.

Historical Stock Returns for Veerhealth Care

1 Day5 Days1 Month6 Months1 Year5 Years
+1.10%+16.31%+28.68%+69.41%+70.85%+177.43%

What specific strategies will Veerhealth Care employ to manage forex volatility as it scales exports to the US and Russia?

How will the recent increase in trade receivables and inventories impact the company's working capital requirements and cash flow in FY27?

What are the expected revenue contributions from the newly onboarded Ayurveer products on Myntra compared to existing e-commerce partnerships?

Veerhealth Care secures ₹2.45 Crores repeat order from FMCG firm

1 min read     Updated on 18 May 2026, 04:33 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Veerhealth Care Limited announced a repeat order worth ₹2.45 Crores from a leading domestic FMCG company for personal care products, scheduled for execution within 45 days. The company, which holds USFDA plant clearance, projects revenues of ₹50-70 crores for FY 2026-27 and aims for ₹100 crores in the next 24 months.

powered bylight_fuzz_icon
40410481

*this image is generated using AI for illustrative purposes only.

Veerhealth Care Limited has secured a repeat order worth ₹2.45 Crores from one of India's leading FMCG companies for the supply of personal care products. The announcement was made on May 18, 2026, in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015.

Order Details

The order pertains to the supply of face care products to a domestic entity. The identity of the client has not been revealed, as the terms of the arrangement are confidential. The company is required to execute the order within a stipulated timeframe of 45 days. The buyer operates in the domestic and international markets in the 'personal and household care' segment and is part of a 125-year-old prominent business group.

The key parameters of the order are summarised below:

Parameter Details
Order Value ₹2.45 Crores
Nature of Order Supply of Face Care Products
Client Type Leading FMCG Company
Client Name Not disclosed (confidential terms)
Order Type Repeat Order
Execution Timeline 45 Days
Order Category Domestic

Future Outlook

Veerhealth Care specializes in manufacturing pure vegetarian toothpaste and has secured USFDA plant clearance, positioning it in a distinctive category among small-cap companies. For the fiscal year 2026-27, the company expects total revenues of ₹50-70 crores with a PAT of 7-10%. However, considering ongoing discussions for orders with both domestic and export buyers, revenues may exceed this guidance. The company anticipates reaching a revenue of ₹100 crores with a PAT of 10% in the next 24 months.

Historical Stock Returns for Veerhealth Care

1 Day5 Days1 Month6 Months1 Year5 Years
+1.10%+16.31%+28.68%+69.41%+70.85%+177.43%

Could this repeat order from a 125-year-old FMCG conglomerate signal a long-term supply agreement, and what is the potential annual revenue Veerhealth Care could derive from scaling this partnership?

How might Veerhealth Care's USFDA plant clearance advantage position it to cross-sell its face care manufacturing capabilities to its existing US-based institutional clients?

Given the company's ayurvedic and natural ingredients focus, could rising consumer demand for clean-label personal care products accelerate Veerhealth Care's transition from oral care to a broader face and skin care contract manufacturer?

More News on Veerhealth Care

1 Year Returns:+70.85%